James McArthur
Chief Executive Officer at PEPGEN INC.
Net worth: 19 820 $ as of 2024-04-29
James McArthur active positions
Companies | Position | Start | End |
---|---|---|---|
PEPGEN INC. | Director/Board Member | - | - |
Chief Executive Officer | 2021-08-05 | - | |
President | - | - | |
Cydan LLC
Cydan LLC Medical DistributorsDistribution Services Cydan LLC operates as an orphan drug accelerator that identifies and de-risks programs. The firm's model evaluates programs for treating rare diseases with unmet medical need and is aimed at creating new companies to develop those therapies. The company was founded by James G. McArthur in 2013 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 2011-12-31 | - |
Founder | 2011-12-31 | - | |
The Friedreich's Ataxia Research Alliance
The Friedreich's Ataxia Research Alliance Information Technology ServicesTechnology Services The Friedreich's Ataxia Research Alliance provides patient registry services. The private company is based in Downingtown, PA. | Director/Board Member | - | - |
Pepgen Ltd.
Pepgen Ltd. Packaged SoftwareTechnology Services Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom. | Director/Board Member | 2021-02-03 | - |
Chief Executive Officer | 2021-02-03 | - | |
President | 2021-02-03 | - |
Career history of James McArthur
Former positions of James McArthur
Companies | Position | Start | End |
---|---|---|---|
T-Cure Bioscience, Inc.
T-Cure Bioscience, Inc. BiotechnologyHealth Technology T-Cure Bioscience, Inc. is an innovative immuno-oncology company based in Sherman Oaks, CA. The private company maintains a pipeline of TCR under clinical and pre-clinical development targeting HERV-E, KK-LC-1, NY-ESO-1, and other antigens associated with solid tumors of significant unmet medical needs, including kidney cancer, breast cancer, lung cancer, gastric cancer, ovarian cancer, liver cancer, pancreatic cancer, sarcoma, and glioblastoma. The CEO of the company is Gang Zeng. | Director/Board Member | 2020-03-31 | 2020-08-31 |
IMARA | Director/Board Member | 2015-12-31 | 2020-04-21 |
Chief Executive Officer | 2015-12-31 | 2018-06-12 | |
Founder | 2015-12-31 | 2020-04-21 | |
President | 2015-12-31 | 2018-06-12 | |
NIGHTSTAR THERAPEUTICS PLC | Director/Board Member | 2016-10-31 | 2019-06-06 |
Independent Dir/Board Member | 2016-10-31 | 2019-06-06 | |
Adheron Therapeutics, Inc.
Adheron Therapeutics, Inc. BiotechnologyHealth Technology Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA. | Chief Tech/Sci/R&D Officer | 2006-05-31 | 2012-08-31 |
Founder | 2006-05-31 | 2012-08-31 | |
Phylogix, Inc.
Phylogix, Inc. Pharmaceuticals: MajorHealth Technology Phylogix, Inc. develops therapeutic drugs. It conducts research on tissue protection and oncology. The firm develops drug candidates in preclinical development, called FRIL to protect cancer patients from the toxic side-effects of chemotherapy. The company was founded in 1998 and is headquartered in Waltham, MA | Chief Tech/Sci/R&D Officer | - | 2009-09-01 |
░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░ ░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - | - |
░░░░░░░ | - | - |
Training of James McArthur
McGill University | Doctorate Degree |
Statistics
International
United States | 12 |
United Kingdom | 4 |
Canada | 2 |
Operational
Director/Board Member | 8 |
Founder | 6 |
Chief Tech/Sci/R&D Officer | 4 |
Sectoral
Health Technology | 11 |
Technology Services | 3 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
PEPGEN INC. | Health Technology |
Private companies | 13 |
---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
Adheron Therapeutics, Inc.
Adheron Therapeutics, Inc. BiotechnologyHealth Technology Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA. | Health Technology |
Phylogix, Inc.
Phylogix, Inc. Pharmaceuticals: MajorHealth Technology Phylogix, Inc. develops therapeutic drugs. It conducts research on tissue protection and oncology. The firm develops drug candidates in preclinical development, called FRIL to protect cancer patients from the toxic side-effects of chemotherapy. The company was founded in 1998 and is headquartered in Waltham, MA | Health Technology |
Cydan II, Inc.
Cydan II, Inc. Pharmaceuticals: GenericHealth Technology Cydan II, Inc. develops and commercializes drugs for orphan and diseases. The firm evaluates products for treating rare diseases with high unmet medical need to start multiple companies to develop such therapies. The company was founded by Cristina Csimma, James G. McArthur, Deborah S. Geraghty and Christoph M. Adams in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Cydan LLC
Cydan LLC Medical DistributorsDistribution Services Cydan LLC operates as an orphan drug accelerator that identifies and de-risks programs. The firm's model evaluates programs for treating rare diseases with unmet medical need and is aimed at creating new companies to develop those therapies. The company was founded by James G. McArthur in 2013 and is headquartered in Cambridge, MA. | Distribution Services |
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Health Technology |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
Imara, Inc.
Imara, Inc. Pharmaceuticals: MajorHealth Technology Imara, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. The company was founded by James Gregg McArthur in 2016 and is headquartered in Brookline, MA. | Health Technology |
Nightstar Therapeutics Ltd.
Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
The Friedreich's Ataxia Research Alliance
The Friedreich's Ataxia Research Alliance Information Technology ServicesTechnology Services The Friedreich's Ataxia Research Alliance provides patient registry services. The private company is based in Downingtown, PA. | Technology Services |
Tiburio Therapeutics, Inc.
Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA. | Health Technology |
Pepgen Ltd.
Pepgen Ltd. Packaged SoftwareTechnology Services Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom. | Technology Services |
T-Cure Bioscience, Inc.
T-Cure Bioscience, Inc. BiotechnologyHealth Technology T-Cure Bioscience, Inc. is an innovative immuno-oncology company based in Sherman Oaks, CA. The private company maintains a pipeline of TCR under clinical and pre-clinical development targeting HERV-E, KK-LC-1, NY-ESO-1, and other antigens associated with solid tumors of significant unmet medical needs, including kidney cancer, breast cancer, lung cancer, gastric cancer, ovarian cancer, liver cancer, pancreatic cancer, sarcoma, and glioblastoma. The CEO of the company is Gang Zeng. | Health Technology |
- Stock Market
- Insiders
- James McArthur
- Experience